Bifogade filer
Preclinical data of tasquinimod in myelofibrosis awarded oral presentation at ASH 2023
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Lund, November 2, 2023 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that two abstracts with preclinical data for tasquinimod in myelofibrosis and myelodysplastic syndrome have been accepted for presentation at the 65th American Society of Hematology Annual Meeting in San Diego, December 9-12, 2023 (ASH 2023). The abstract demonstrating efficacy of tasquinimod in myelofibrosis has been selected for an oral presentation. The accepted abstracts for ASH 2023 were published today, November 2, 2023.
The abstract, entitled Preclinical studies demonstrating efficacy of tasquinimod in models of advanced myeloproliferative neoplasm (MPN) in blastic phase, will be presented as an oral presentation by Dr. Warren Fiskus, PhD, MD Anderson Cancer Center, Texas, USA. The abstract is a result of the collaboration between Active Biotech and Professor Kapil Bhalla´s research group at MD Anderson, which primarily aims to clarify tasquinimod's mechanisms and effects in myelofibrosis. Data to be presented demonstrate efficacy of tasquinimod as monotherapy and in combination with frontline therapies in models of advanced myelofibrosis.
In addition, the abstract entitled Tasquinimod improves erythropoiesis and mitigates bone loss in myelodysplastic mice will be presented as a poster by Dr. Manja Wobus, University Hospital Dresden, Germany. The abstract comes from our collaboration with Dr Wobus in Dresden, showing the first evidence for an in vivo effect of tasquinimod in a murine model of MDS, by significantly improving red blood cell counts and decreasing bone loss.
"The data to be presented suggest that treatment with tasquinimod has the potential both in monotherapy and in combination with other therapies to have a broad effect on myelofibrosis and MDS. We are very pleased and honored to have the opportunity to present our data at such a prestigious conference as ASH, which shows the external scientific interest in tasquinimod in this disease area," said Helén Tuvesson, CEO of Active Biotech.
Information on the presentations:
Publication Number: 741 Preclinical Studies Demonstrating Efficacy of Tasquinimod in Models of Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase, Warren Fiskus et al.
Session Name: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Stromal-Immune and Signaling Context
Session Date: Monday, December 11, 2023
Session Time: 10:30 AM - 12:00 PM
Presentation Time: 11:00 AM
Room: San Diego Convention Center, Ballroom 20AB
Publication Number: 2798 Tasquinimod Improves Erythropoiesis and Mitigates Bone Loss in Myelodysplastic Mice, Manja Wobus et al.
Session Name: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II
Session Date: Sunday, December 10, 2023
Presentation Time: 6:00 PM - 8:00 PM
Location: San Diego Convention Center, Halls G-H
The abstracts will be available online on ASH's website from 09:00 Eastern time (14:00 CET) on November 2, 2023.